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Abstract
Objective To assess the cost effectiveness of the Find and Treat service
for diagnosing and managing hard to reach individuals with active
tuberculosis.
Design Economic evaluation using a discrete, multiple age cohort,
compartmental model of treated and untreated cases of active
tuberculosis.
Setting London, United Kingdom.
Population Hard to reach individuals with active pulmonary tuberculosis
screened or managed by the Find and Treat service (48 mobile screening
unit cases, 188 cases referred for case management support, and 180
cases referred for loss to follow-up), and 252 passively presenting
controls from London’s enhanced tuberculosis surveillance system.
Main outcome measures Incremental costs, quality adjusted life years
(QALYs), and cost effectiveness ratios for the Find and Treat service.
Results The model estimated that, on average, the Find and Treat
service identifies 16 and manages 123 active cases of tuberculosis each
year in hard to reach groups in London. The service has a net cost of
£1.4 million/year and, under conservative assumptions, gains 220
QALYs. The incremental cost effectiveness ratio was £6400-£10
000/QALY gained (about €7300-€11 000 or $10 000-$16 000 in
September 2011). The two Find and Treat components were also cost
effective, even in unfavourable scenarios (mobile screening unit (for
undiagnosed cases), £18 000-£26 000/QALY gained; case management
support team, £4100-£6800/QALY gained).
Correspondence to: I Abubakar ibrahim.abubakar@hpa.org.uk
Extra material supplied by the author (see http://www.bmj.com/content/343/bmj.d5376/suppl/DC1)
Web appendix: Detailed justification for state transition parameters in model
Video on bmj.com (see also http://bmj.com/video)
This film explains more about the outreach service and shows why it is important to take the service to the patient, rather than the other way round.
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RESEARCHConclusions Both the screening and case management components
of the Find and Treat service are likely to be cost effective in London.
The cost effectiveness of the mobile screening unit in particular could
be even greater than estimated, in view of the secondary effects of
infection transmission and development of antibiotic resistance.
Introduction
The incidence of tuberculosis in the UK has increased
consistently over the past two decades.
1 2 More than 9000 cases
arereportedeveryyear,with38%ofcasesoccurringinLondon.
2
This increase has been associated with a change in the
epidemiology of the disease: although tuberculosis affected the
general population in the past, most cases now occur in high
risk groups. In particular, tuberculosis is widely recognised to
be associated with social risk factors, including homelessness,
problematic drug use, and imprisonment.
3 Previous work
suggests that the outcome of care in these population groups is
probably suboptimal.
3 4 In a recent study, the estimated
prevalence of tuberculosis in hard to reach groups in London
was 788 per 100 000 in homeless people, 354 per 100 000 in
people with problematic drug use, and 208 per 100 000 in
prisoners.Bycomparison,theoverallprevalenceoftuberculosis
in London was 27 per 100 000 people.
3 Although only 17% of
tuberculosis cases in London are in hard to reach people, they
account for nearly 38% of non-treatment adherent cases, 44%
of cases lost to follow-up, and 30% of all highly infectious
cases.
3 Tuberculosis control therefore needs targeted
interventions to address transmission in these groups.
In April 2005, the English Department of Health provided
funding to set up a mobile radiography unit to actively screen
for tuberculosis disease in London’s vulnerable populations, in
view of their low rate of presentation for passive care. The
service visits locations where high risk groups can be found,
including drug treatment services and hostels or day centres for
homelessandimpoverishedpeople.Allindividualsarescreened
on a voluntary basis regardless of symptom status.
Since September 2007, the mobile screening unit has been
encompassedbythe“FindandTreat”service.Thisserviceaims
not only to screen and find active cases, but also to raise
awareness, undertake case holding, and provide support for
treatment completion for the same hard to reach groups. The
unit has visited 210 locations across most London primary care
trusts,withamedianof52individualsscreenedateachlocation
per year. The service uses links with drug and alcohol support
services,hostels,andstreetoutreachandcriminaljusticeservices
to find cases and to maintain contact with patients during
treatment to ensure completion. The availability of staff
members to accompany patients to appointments and for home
visits reduces the risk of cases being lost to follow-up.
Awareness raising events take place in venues across London
such as hostels, which are particularly supported by peer
workers—individualsfromhighriskgroupswhohavecompleted
treatment for tuberculosis. The service not only oversees cases
referred by the mobile screening unit, but also those referred
by tuberculosis clinics across London, who are non-adherent to
treatmentorlosttofollow-upcarebeforetreatmentcompletion.
Mobile screening services have also been successfully trialled
in the Netherlands and Zimbabwe,
5 6where they seem to have
potentially rapid effects on tuberculosis transmission and
disease.
5 The UK secretary of state for health has recently
suggested that initiatives like the Find and Treat service could
be implemented in cities such as Birmingham, where the
prevalence of tuberculosis is rising.
7
We aimed to evaluate the cost effectiveness of the Find and
Treat service from September 2007 to July 2010 in London,
using a decision analytical model set up with patient level data.
As the service reaches the end of its pilot phase, the economic
assessmentoftheseinterventionswillhelptoinformkeypolicy
decisions on tuberculosis control in London and elsewhere.
Methods
Decision problem
WeevaluatedthecosteffectivenessoftheFindandTreatservice
by considering costs and outcomes of three groups: patients
identified by the mobile screening unit with active pulmonary
tuberculosis on chest radiograph examination and further
diagnostic tests, patients referred to the service for enhanced
case management support (that is, to ensure they complete
treatment successfully), and patients referred to the service
because they had been lost to follow-up. As controls in our
study, we used the current method of passive case finding
combined with ad hoc outreach in some primary care trusts,
because no other interventions targeting hard to reach cases of
tuberculosis have been trialled in London. We compared the
following options: having no Find and Treat service, having
only one part of the service (the mobile screening unit or the
case management component), and having both parts of the
service. We undertook the evaluation from the perspective of
the healthcare taxpayer perspective.
Data sources
We used the Find and Treat database to obtain information on
individuals with active pulmonary tuberculosis screened or
managed by the service with record dates between September
2007 and September 2010. Records were not available before
September 2007. Although the service used to screen a large
numberofprisoners,ithasmostlystoppedsincetheintroduction
ofradiographmachinesinprisonsforactivecasefindinginnew
inmates.
Cases detected by the mobile screening unit and engaged with
the Find and Treat service were compared with passively
detected control cases with active pulmonary tuberculosis (that
is, individuals who presented to London tuberculosis services
of their own accord without screening and referral to the Find
and Treat service). We excluded patients with non-pulmonary
tuberculosis since they would not be detected by chest
radiography. A passively presenting group was the most
appropriatecontrol,becausetheyreceivedthecareservicesthat
would be available in London in the absence of Find and Treat.
We selected controls from passively detected cases in London
that were notified to the Health Protection Agency’s enhanced
tuberculosissurveillancesystem
2between1January2009(when
the system began recording risk factor information) and 9
August 2010. We chose controls that were age matched with
actively detected cases (within five year age categories) and
that displayed one or more risk factors (a history of
homelessnessorimprisonment,drugoralcoholabuse,ormental
health problems).
We obtained risk factor and clinical information for Find and
Treatcasesandpassivelypresentingcontrolsfromtheenhanced
tuberculosis surveillance system. Case information was
supplemented with data from the Find and Treat database. For
each Find and Treat patient, we obtained the date of first screen
(for those referred by the mobile screening unit), treatment
outcome, and date of outcome, by matching patients to records
in the enhanced tuberculosis surveillance system. For patients
with symptoms on screening, we calculated diagnostic delays
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treatment. We obtained dates of symptom onset and treatment
by approaching individual clinics when they were not recorded
inthedatabases.Ifthedateofsymptomonsetwasnotavailable,
we used the date when the patient sought clinical help. We
calculated times to the final outcome as the difference between
the date when the service engaged the patient and the date of
treatment or episode completion.
The study included 75 mobile screening unit cases, 231 cases
referred for case management support, 263 cases referred
followinglosstofollow-up,and315passivelypresentedcontrol
cases.Weexcludedcasesofextrapulmonarytuberculosis,latent
tuberculosis,andsuspectedtuberculosis;casesmerelyreceiving
prophylaxis (and hence unlikely to have active tuberculosis);
cases for which the diagnostic delay could not be calculated;
and cases younger than 16 years. After these exclusions, the
study had 48 mobile screening unit cases, 188 cases referred
for case management support, 180 cases referred for loss to
follow-up, and 252 passively presenting control cases.
Compartmental model structure
We used a discrete, multiple age cohort, compartmental model
8
to model a population of individuals with active tuberculosis.
Individuals in the model can occupy one of four health states:
active untreated tuberculosis, active treated tuberculosis with
up to 125 days of continuous treatment, active treated
tuberculosis with more than 125 days of continuous treatment,
and lost to follow-up. We split patients undergoing treatment
bydurationoftreatment(witha125daycutoff),whichprovided
abetterfittodata(webappendix).Inourmodel,patientsmoved
betweenthesehealthstatesastheystartedtreatment,completed
treatment,werelosttofollow-up,andre-engagedwithtreatment
(fig⇓).
Every year, cases also have a probability of entering four final
outcomes (from which they do not leave): completion of
treatment, death due to tuberculosis related causes, death due
toothercauses,andotherfinaloutcomesthattheFindandTreat
service is not expected to change (such as patients being
transferred out of London or stopping treatment for clinical
reasons). To estimate the rate of death from causes not related
to tuberculosis, we used 2009 all cause mortality rates from the
Office for National Statistics. The model followed patients for
the remainder of their lives.
The model included actual cases of active pulmonary
tuberculosis that had been recorded as screened or managed by
the Find and Treat service between September 2007 and
September 2010. Since the recruitment period covered three
years, we estimated that, on average, the service identified 16
andmanaged123individualswithactivetuberculosiseachyear.
Patients entered the model at the age when they were recorded
asbeingdetectedbythemobilescreeningunitorreferredtothe
service for case management.
Foreachcasecategory(thatis,casesscreened,referredbecause
of complex management issues, or referred after loss to
follow-up), we compared the outcomes of a model cohort
managed by the Find and Treat service with the outcomes of an
equivalent cohort not managed by the service (based on
passively detected controls). We then estimated the rates of
transition between health states (table 1⇓). We assumed that
Find and Treat cases without confirmed active tuberculosis had
no additional health benefit or detriment as a result of
encountering the service.
Costs and quality of life weights
Untreated cases of active tuberculosis were assumed to have a
utility score of 0.68 (standard error 0.5), based on the mean
EQ-5D score given to cases diagnosed with tuberculosis in
London
9 (individual level data obtained from M Kruijshaar,
personal communication). The EQ-5D is a standardised
instrumentusedtomeasurequalityoflifeanditsuseispreferred
by the National Institute for Health and Clinical Excellence
(NICE). This utility score of 0.68 was also reported in a
Canadian study using an alternative instrument to measure
quality of life, the SF-6D.
10 For the patients in London, EQ-5D
scores improved to 0.81 (standard error 0.04) after 2 months of
treatment. Hence we assumed that in the first year of treatment,
patientswouldhaveanintermediateutilityscoreof0.79,before
reachingascoreof0.81insubsequentyears.
9Weassumedcases
without active tuberculosis to have the same utility score as
populationnorms.
11Table2⇓summarisestheeconomicvariables
used in the model.
We obtained costs for staff salaries, training and development,
travel and subsistence, administration, maintenance, cleaning,
insurance,fuel,officemanagement,andradiographyequipment
maintenance in 2009-10 from the Find and Treat records. We
increasedstaffcoststotakeintoaccountqualificationandcapital
overhead costs, by mapping job descriptions of Find and Treat
staff to their nearest equivalents (in terms of role and salary)
fromstandardcostingsources.
12Wedidnotincludenon-capital
overhead costs, since these were already part of the Find and
Treat annual budget.
Chest radiography costs were already included in the overall
Find and Treat budget. Patients referred for diagnostic testing
(regardless of whether they were subsequently found to have
active tuberculosis) were assumed to incur the cost of a
laboratory culture test, estimated from the tariff cost for
microbiological pathology services.
13 We estimated the cost of
treating a case of tuberculosis from NICE guidelines.
14 Also,
increased treatment costs were associated with multidrug
resistantpatients.
14BasedonFindandTreatdata,0.5%ofmobile
screeningunitpatientsand5.3%ofotherFindandTreatpatients
had multidrug or extensively drug resistant infection (table 1);
the remaining patients’ infections were not resistant or were
resistant to only one drug. We inflated costs to 2009-10 prices
usingthehospitalandcommunityhealthservicespayandprices
index.
12
We then added up the costs incurred and quality adjusted life
years(QALYs)associatedwitheachhealthstate(fig),withand
withouttheFindandTreatservice,withfuturecostsandbenefits
discounted at a rate of 3.5% per year as recommended by
NICE.
15
To determine the cost effectiveness of the two components of
the Find and Treat service, we allocated costs between the
mobilescreeningunitandthecasemanagementteamaccording
to the estimates given in the Find and Treat budget (including
qualification and capital overhead costs). However, we
transferred an additional amount from the case management
service budget to the mobile screening unit budget to represent
enhanced follow-up of screened cases, based on the proportion
of cases followed up who were identified by the mobile
screening unit.
Sensitivity analysis
To test the robustness of the results, we made several
assumptions (individually and in combination) that were less
favourable to Find and Treat.
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Instead of using standard UK National Health Service capital
overheadsforthecostoftheunit,weassumedthatanewmobile
unit would need to be purchased, and that it would last five
years before being decommissioned. We assumed the cost of a
new unit to be £600 000 (excluding maintenance costs, which
were already incorporated in the unit’s running budget). We
added this amount to the costs of the first year of the service,
with discounted costs and outcomes totalled over five years.
Increased cost of tuberculosis treatment
Instead of using costs for tuberculosis treatment from a NICE
report, we used higher figures from a costing study,
16 and
inflated them to 2009-10 prices using the pay and prices index
for hospital and community health services. This gave costs of
£8300and£75000fortreatmentofdrugsensitiveandmultidrug
resistant tuberculosis, respectively.
12
Improved quality of life for untreated tuberculosis
case, and poor quality of life for tuberculosis
cases on treatment
We raised the QALY weight for untreated tuberculosis cases
to the upper 95% limit of the sampling distribution of its mean
(utility score 0.76). We also lowered the QALY weight for
treated tuberculosis cases to 0.76 (so that putting patients on
treatmentisnotassumedtoprovideabetterhealthrelatedquality
of life until treatment is completed).
Asymptomatic cases detected by mobile
screening unit do not always progress to
symptomatic disease
We assumed that only 50% of asymptomatic cases with a
positive result from the mobile screening unit would progress
to symptomatic disease.
Cases referred to Find and Treat service for
enhanced case management have a reduced
loss to follow-up rate in the absence of the
service
We assumed that Find and Treat cases would be lost to
follow-upatthesamerateasenhancedtuberculosissurveillance
controls (17.2% per year) in the absence of the service, rather
than at the higher rate we estimated for this extremely hard to
reach group (34.7% per year).
Cases referred to Find and Treat service for loss
to follow-up could still passively re-engage with
treatment
We assumed that even without Find and Treat involvement,
these cases could still passively re-engage with treatment at the
same rate as enhanced tuberculosis surveillance controls (51%
per year).
Results
Transition rates of cases managed and not
managed by Find and Treat
The web appendix provides estimated values and full details of
the estimation procedure used to compare the transition rates
between health states in the two cohorts.
Previously untreated cases referred for treatment
after detection by mobile screening unit
We estimated that the 22.9% of patients detected by the mobile
screening unit with the longest delays between symptom onset
andtreatmentpresentationwereunlikelytopresentfortreatment
withouttheactivitiesoftheFindandTreatservice.Furthermore,
35.4% of mobile screening unit patients were asymptomatic on
detection, and hence would not have presented for treatment
withouttheunit.Weassumedthatasymptomaticpatientswould
progress rapidly to symptomatic disease,
17 and that in the
absence of the Find and Treat service, they would behave
similarly to symptomatic patients (that is, some would present
fortreatment,but22.9%wouldnot).Onceontreatment,mobile
screeningunitcasesmanagedbytheFindandTreatservicehad
amuchlowerriskoflosstofollow-upthanpassivelypresenting
controls (loss to follow-up probability after one year: 2.1% for
cases, 17.2% for controls).
Cases referred to Find and Treat service for case
management support
We found that cases referred to Find and Treat because of
complexcasemanagementissueshadhigherratesofcompleting
treatment (61.2% after one year) and lower rates of loss to
follow-up (3.3% after one year) than controls.
Cases under treatment referred to Find and Treat
service because of loss to follow-up
We estimated that 51.7% of cases of active pulmonary
tuberculosis referred to the Find and Treat service because of
loss to follow-up would subsequently return to the service. We
estimated cases become lost to follow-up after re-engagement
at an annual rate of 34.7%. Once this happens, we estimated
thattheannualprobabilityofre-engagementifcaseswereagain
lost to follow-up was 81.7%; we assumed the remaining cases
to be permanently lost. Since these lost cases have little hope
of re-engaging with treatment after referral, we assumed that,
in the absence of the Find and Treat service, these cases would
not be re-engaged.
Cost effectiveness of Find and Treat service
Table 3⇓ shows the costs incurred and QALYs accrued by the
cohort of active tuberculosis cases described in this report, for
scenarios with and without the Find and Treat service. We
estimated that every year the service has a net cost of £1.4
million and gains 220 QALYs. Hence the incremental cost
effectiveness of the Find and Treat service was estimated to be
£6400/QALYgained.Thewebappendixshowshowtheservice
affects the health state of cases over time.
We also found both components of the service to be cost
effective at the same threshold. The mobile screening unit had
anincrementalratioof£18000/QALYgained,whereasthecase
management component had an incremental ratio of
£4100/QALYgained.Theratioincreasedslightlywhenweused
assumptions that were more unfavourable to the Find and Treat
service, but not enough to change the overall conclusion (table
4⇓). In the most unfavourable (and highly unlikely) scenario,
which combined all the unfavourable assumptions, the mobile
screening unit and case management components had
incremental ratios of £26 000/QALY gained and £6800/QALY
gained, respectively.
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Principal findings, strengths, and limitations
of study
The Find and Treat service appears to be cost effective, based
on a threshold of £20 000-£30 000/QALY gained, used by
NICE.
15 Although analyses of each Find and Treat component
shouldbeinterpretedwithcautionbecauseofoverlappingcosts
between the two services, they both seem to be cost effective
separately. We obtained similar results when we made
assumptions that were more unfavourable to the Find and Treat
service. In the most unfavourable case, in which data were
interpretedunfavourablyinfiveinstancestocreateaveryhighly
unlikelyscenario,themobilescreeningunithadanincremental
cost effectiveness ratio of about £26 000 (table 4). NICE would
oftenstillconsiderthisratiotobeacceptable,
15particularlysince
during model parameterisation, whenever data were not
available, we made conservative assumptions to ensure that the
benefit of Find and Treat was not overestimated.
One limitation of our analysis is the absence of a trial
randomising tuberculosis cases to be either managed or not
managed by the Find and Treat service. The absence of
randomisation meant that we could not be sure of the outcomes
of Find and Treat managed cases if the service did not exist.
Consequently,webasedourmodelofsuchoutcomesoncontrols
with active tuberculosis in London’s enhanced tuberculosis
surveillancesystemwhopresentedforcare.Althoughwechose
controls to have at least one risk factor to represent the potential
targetpopulationfortheFindandTreatservice,theservicealso
manages extremely hard to reach individuals, who are often
already lost to follow-up at the time of referral or who would
neverpresentforcarewithoutthemobilescreeningunit.Hence
the comparison of cases with retrospective controls probably
underestimates the incremental benefit of the service, although
we cannot be certain without a randomised study.
Furthermore, the methods used for the modelling do not fully
capture the benefits of the Find and Treat service. For example,
wedidnotincorporatesecondarytransmissionintotheeconomic
evaluation, even though the mobile screening unit in particular
probably averts several secondary cases by finding highly
infectiousindividuals.Forexample,inastudyofalargeongoing
epidemicofisoniazidresistanttuberculosisinLondonin2004,
18
researchers found 87 cases with traceable contacts, who had
525 contacts between them. Of these contacts, 355 completed
screening and 11% of these screened contacts became cases.
Another simplification was that we did not measure the effect
of the Find and Treat service on reducing the likelihood of
patients developing and transmitting acquired drug resistance
(as a result of poor treatment adherence). Drug resistance
increases the duration and costs of treatment, as well as the risk
ofseveredisease,thuspreventioncouldbeanimportantbenefit
of the service. Full capture of these benefits would need a
dynamic transmission model. However, since both Find and
Treat components already seem cost effective without
incorporatingdynamiceffects,theuseofastaticmodelappears
to be justified.
Comparisons with other studies and
implications
There is wide international consensus that the provision of
untargetedchestradiographexaminationtothewholepopulation
for tuberculosis detection is largely ineffective.
17 19 There is also
agreement that prompt diagnosis and adequate treatment of
active cases is the most crucial element of tuberculosis control.
Evaluations of interventions to actively find cases, such as
radiologicalscreeningofhighriskgroups,suggestthatnotonly
can the screening of high risk groups detect cases more
effectively than door to door symptom based screening,
5 but
also that transmission can be interrupted when the intervention
is appropriately targeted.
6 The accompanying editorial to the
trial by Corbett and colleagues, while supporting active case
finding in high prevalence groups, argued that any attempt to
scale up such interventions in the community should be
accompanied by systems that ensure treatment completion and
an assessment of cost effectiveness.
20
London has seen a resurgence of tuberculosis on a scale not
seen in any other western European capital in the past two
decades.
21-23 The incidence of tuberculosis in the London
borough of Brent is comparable to that in Karonga District in
Malawi.
2 24 It is therefore appropriate that any intervention that
provides a cost effective means to identify cases promptly and
ensure that they complete treatment is an essential component
of the tuberculosis control programme. This study shows that
the Find and Treat service provides an intervention that detects
hard to reach cases of symptomatic and asymptomatic
tuberculosis, and ensures that they receive treatment. The cost
effectiveness compares favourably with other interventions
currently funded to control tuberculosis in the UK.
14 For
example, the dual strategy of tuberculin skin testing and
interferon gamma release assay testing has an incremental cost
effectiveness ratio of £29 955/QALY gained, and universal
BCG vaccination of school children has a ratio of £56
000/QALY gained (assuming 0.05% infection prevalence and
10 years of vaccine protection).
The true value of the Find and Treat service to public health
will only fully be realised when a cost effective rapid point of
care diagnostic tool becomes available. Although there are
promisingreportsofrapidmoleculartestsendorsedbytheWorld
Health Organization,
25 26 there is currently no test to accurately
detect true latent infection, and molecular assays would benefit
from further field evaluation in this setting.
In conclusion, this study shows that the London Find and Treat
service is a cost effective intervention. Indeed, both the
screening and case management support components of the
intervention are likely to be cost effective in London. Although
the Find and Treat service alone will probably not reverse the
rise in tuberculosis in London, it will probably be helpful to the
individuals who have the greatest evidence of ongoing
transmission.
27Furtherstudiesshouldassessusingpointofcare
testing within community outreach settings such as the mobile
screening unit, as well as the role of community based delivery
oftreatment.Additionally,arandomisedtrialcomparingpatients
managed and not managed by the Find and Treat service would
enableestimatesoftheservice’sbenefitstobemadewithgreater
certainty.
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RESEARCHTables
Table 1| Yearly transition rates (%) in model for cases detected or managed by Find and Treat service and for passively treated control
cases
Control cases Find and Treat cases
Previously untreated cases referred for treatment after screening by Find and Treat service
46.2 54.6 Completed treatment (if in first year of treatment)
56.8 67.1 Completed treatment (if in subsequent year of treatment)
17.2 2.1 Lost to follow-up
0 0 Died from tuberculosis related causes
8.5 10.1
Had final outcome other than treatment completion, tuberculosis related death, or
loss to follow-up
51.0 51.0 Re-engaged with treatment after loss to follow-up
Cases referred to Find and Treat service for case management support because of complex issues
51.7 61.2 Completed treatment
3.3 3.3 Died from tuberculosis related causes
34.7 2.6 Lost to follow-up
9.6 11.3 Had final outcome other than treatment completion, tuberculosis related death, or
loss to follow-up
51.0 51.0 Re-engaged with treatment after loss to follow-up
Cases under treatment referred to Find and Treat service because of loss to follow-up
0 81.7 Re-engaged with treatment (of the 51% who do eventually re-engage)
34.7 34.7 Lost again to follow-up (if on treatment)
40.8 41.0 Completed treatment (if on treatment)
2.6 2.2 Died from tuberculosis related causes
7.6 7.6 Had final outcome other than treatment completion, tuberculosis related death, or
loss to follow-up
Untreated cases*
22.9 22.9 Died from tuberculosis related causes
21.0 21.0 Recovered
Categories specific to Find and Treat cases
– 35.4 Cases with asymptomatic active tuberculosis (as % of mobile screening unit cases)
– 22.9 Extremely hard to reach cases (diagnostic delay >131 days) (as % of mobile
screening unit cases)†
– 51.7 Cases that are found and re-engage with treatment (as % of active tuberculosis
cases referred to Find and Treat service for loss to follow-up)
Multidrug resistant or extensively drug resistant active tuberculosis cases‡
– 0.5 Mobile screening unit cases
– 5.3 Other Find and Treat cases
Rates estimated by matching Find and Treat records to enhanced tuberculosis surveillance data, unless stated otherwise.
*Rates estimated by analysis of cases from south Indian study.
28
†Includes cases that would not be diagnosed without mobile screening unit.
‡Rates estimated by analysis of Find and Treat records.
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RESEARCHTable 2| Economic variables in model
Source Cost/utility score
Find and Treat service
Find and Treat budget* £530 024 Mobile screening unit
Find and Treat budget† £512 825 Case management team
Treatment (per case)
NICE report
16 £5522 Non-multidrug resistant tuberculosis
NICE report
16 £31 329 Multidrug resistant tuberculosis
National Health Service reference costs
15 £7.12 Tuberculosis sputum test
Quality of life weights
EQ-5D study
11 0.68 Active tuberculosis, untreated
EQ-5D study
11 0.79 Active tuberculosis, first year of treatment
EQ-5D study
11 0.81 Active tuberculosis, second and subsequent year of treatment
*Breakdown of costs: staff costs for registrar, nurse, administrator, driver, and radiographer (£345 624); training and development (£20 000); travel and subsistence
(£4800); contracted administration (£15 000); maintenance and cleaning (£25 000); insurance and fuel (£18 000); radiography maintenance (£50 000); and office
and management (£51 600).
†Breakdown of costs: staff costs for nurse, social worker, outreach worker, clinical lead and contracted nurse (£361 225); training and development (£30 000);
travel and subsistence (£3200); contracted administration (£15 000); and office and management (£103 400).
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RESEARCHTable 3| Costs incurred and QALYs accrued by active tuberculosis cases with and without Find and Treat service
Difference Without Find and Treat With Find and Treat
Costs incurred
£1 000 000 £0 £1 000 000 Find and Treat service
£400 £330 £730 Diagnostic tests
£400 000 £310 000 £690 000 Treatment
£1 400 000 £310 000 £1 700 000 Total
QALYs accrued
4 87 91 Mobile screening unit for hard to reach patients
19 29 48 Mobile screening unit for extremely hard to reach patients
13 65 78 Mobile screening unit for asymptomatic cases
60 520 580 Referrals because of complex case management issues
130 220 350 Referrals because of loss to follow-up
220 920 1100 Total
£6400 – – Incremental cost effectiveness ratio
Data are rounded to 2 significant figures.
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RESEARCHTable 4| Cost effectiveness comparison of Find and Treat components under unfavourable scenarios
Incremental cost effectiveness ratio
Scenario
Case management Mobile screening unit Find and Treat service (components
combined)
£4100 £18 000 £6400 Base case
£4100 £20 000 £6700 Increased mobile screening unit costs
£5600 £18 000 £7600 Increased treatment costs
£4200 £19 000 £6500 Improved quality of life for untreated tuberculosis and poor quality of life
for treated tuberculosis
£4100 £22 000 £6500 Asymptomatic mobile screening unit cases do not always progress to
symptomatic disease
£4600 £18 000 £7100 Cases referred to Find and Treat service for enhanced case management
have lower rate of loss to follow-up than those not referred
£4700 £18 000 £7500 Cases referred to Find and Treat service for loss to follow-up could
passively re-engage with treatment
£6800 £26 000 £10 000 Most unfavourable scenario to Find and Treat service*
Data rounded to 2 significant figures. *All scenarios combined, apart from base case.
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RESEARCHFigure
Health states in compartmental model for active tuberculosis cases, managed by the Find and Treat service
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RESEARCH